Pervyy opyt primeneniya alemtuzumaba u bol'nykh khronicheskim limfoleykozom,refrakternykh k fludarabinsoderzhashchim programmam khimioterapii
- 作者: Zagoskina T1, Malykh O1, Khorobrykh M1, Dem'yanova V1, Isaeva N1, Grishina I1
-
隶属关系:
- ФГУ Кировский НИИ гематологии и переливания крови Росмедтехнологий
- 期: 卷 10, 编号 3 (2008)
- 页面: 52-55
- 栏目: Articles
- URL: https://journals.rcsi.science/1815-1434/article/view/26734
- ID: 26734
如何引用文章
全文:
详细
作者简介
T Zagoskina
ФГУ Кировский НИИ гематологии и переливания крови Росмедтехнологий
O Malykh
ФГУ Кировский НИИ гематологии и переливания крови Росмедтехнологий
M Khorobrykh
ФГУ Кировский НИИ гематологии и переливания крови Росмедтехнологий
V Dem'yanova
ФГУ Кировский НИИ гематологии и переливания крови Росмедтехнологий
N Isaeva
ФГУ Кировский НИИ гематологии и переливания крови Росмедтехнологий
I Grishina
ФГУ Кировский НИИ гематологии и переливания крови Росмедтехнологий
参考
- Eichhorst B.F., Busch R, Stauch M et al. Fludarabine indused higher response rates in fist line therapy of older patients with advanced chronic lymphocytic leukemia than chlorambucil: interim analysis of a phase III study of the German CLL Study Group (GCLLSG). Blood 2003; 102: Abstr. 369.
- Tothova E, Kafkova A, Fricova M et al. Fludarabine combined with cyclophosphamide is an efficient treatment for advanced chronic lymphocytic leukemia. Neoplasma 2003; 50: 433–7.
- Wierda W, O'Brien S, Wen S et al. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol 2005; 23: 4070–8.
- Keating M, O'Brien S, Albitar M et al. Early results of chemoimmunotherapy regimen of fludarabine, cyclophosphamide and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005; 23: 2979–1088.
- Бялик Т.Е., Волкова M.A., Загоскина Т.П. и др. Флударабин в лечении хронического лимфолейкоза: Гематол. и трансфузиол. 2004; 3: 6–11.
- Eichhorst B.F., Bush R, Hopfinger G et al. Fludarabine plus cyclophosphamide (FC) versus fludarabine alone in first line therapy of younger patients with chronic lymphocytic leukemia. Blood 2006; 107: 885–91.
- Kowal M, Dmoszynska A, Levanovski K et al. Efficacy and safety of fludarabine and cyclophosphamide combined therapy in patients with refractory/recurrent B - cell chronic lymphocytic leukemia (B-CLL)-Polish multicentre study. Leuk. Lymphoma 2004; 45: 1159–65.
- Bosch F, Ferrer A, Lopez-Guillermo A et al. Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia. Br J Haematol 2002; 119: 976–84.
- Leporrier M. Role of fludarabine as monotherapy treatment of chronic lymphocytic leukemia. Hematol J 2004; 5: S10–9.
- Hendry L, Bowen A, Matutes E et al. fludarabine, cyclophosphamide and mitoxantrone in relapsed or refractory chronic lymphocytic leukemia and low grade non - Hodgking's lymphoma. Leuk. Lymphoma 2004; 45: 945–50.
- Rai K.R., Freter C.E., Mercier R.J. et al. Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. J Clin Oncol 2002; 20: 3891–7.
- Keating M.G., Flinn I, Jain V et al. Therapeutic role of alemtusumab (Campath- 1H) in patients who have failed fludarabine: results of a large international study. Blood 2002; 99: 3554–61.
- O'Brien S.M., Kantarjian H.M., Thomas D.A. et al. Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia. Cancer 2003; 98: 2657–63.
- Cheson B.D., Bennett J.M., Grever M et al. National Cancer Institute - sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996; 87 (12): 4990–7.
- Moreton P, Kennedy B, Lukas G et al. Eradication of minimal residual disease in B - cell chronic lymphocytic leukemia after alemtusumab therapy is associated with prolonged survival. J Clin Oncol 2005; 23 (13): 2971–9.
- Pedkins J, Flinn J, Howard R et al. Frequency and type of serious and small lymphocytic lumphoma: implication for clinical trials in this patient population. Cancer 2002; 94: 2033–9.
- Lundin J, Porwit McDonald A, Rossmann E. Cellular immune reconstitution after subcutaneous alemtusumab (anti-CD52 monoclonal antibody, Campath- 1H) treatment as first - line therapy for B - cell chronic lymphocytic leukemia (B- CLL). Leukemia 2004; 18: 484–90.